Is testosterone appropriate for women?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Testosterone has one evidence based use in women. The 2019 Global Consensus Position Statement supports it only for postmenopausal women with hypoactive sexual desire disorder diagnosed after a full assessment. It is not supported for energy, mood, cognition, bone density or wellbeing. There is no FDA approved testosterone product for women in the United States.
Testosterone therapy for women has one supported indication and a long list of unsupported ones. The 2019 Global Consensus Position Statement, endorsed by endocrine and menopause societies internationally, states that the only evidence based indication is treatment of postmenopausal women diagnosed with hypoactive sexual desire disorder after formal biopsychosocial assessment. Everything else marketed to women as testosterone therapy sits outside that evidence.
What the evidence supports
In postmenopausal women with hypoactive sexual desire disorder, trials of testosterone at female physiological doses showed increases in sexual desire, arousal, orgasmic function, pleasure and responsiveness, with a reduction in sexual distress. The size of the effect is modest and worth knowing before starting: an average of one additional satisfying sexual event per month compared with placebo. The consensus statement rates this Level I, Grade A evidence, so the effect is real. It is also small.
What the evidence does not support
The consensus panel found insufficient evidence for testosterone in women for cognition, bone mineral density, mood or depression, general wellbeing, and long term cardiovascular safety, and found no support for use in premenopausal women for any indication. It also states that a blood total testosterone level should not be used to diagnose the condition, and that no cutoff for any circulating androgen distinguishes women with sexual dysfunction from women without. Systemic DHEA is not associated with meaningful improvement in libido and is not recommended.
Products, doses and monitoring
| Question | What the 2019 consensus says |
|---|---|
| Is there an approved product for women? | No approved female product in the US, so approved male formulations are used off label at a fraction of the male dose |
| Compounded testosterone? | Not recommended because of insufficient evidence on efficacy and safety |
| Pellets and injections? | Not recommended, because they produce supraphysiologic levels |
| How is it monitored? | Baseline total testosterone, repeat at 3 to 6 weeks, then every 6 months to detect overdosing |
| How long before deciding? | Stop if there is no clinical benefit by 6 months |
If testosterone is being suggested for fatigue, brain fog, muscle or weight, ask which trial supports that use. Safety data beyond 24 months of treatment do not exist, and the trials largely excluded women at high cardiometabolic risk. If desire is genuinely the problem, ask for a proper assessment first, since relationship factors, pain with sex, antidepressants and untreated vaginal dryness are more common causes than androgen levels.
The clinical detail
The 2019 Global Consensus Position Statement recommends measuring baseline total testosterone, repeating at 3 to 6 weeks after starting to exclude supraphysiologic concentrations, then monitoring every 6 months. Where a compounded product is unavoidable, it should come from a pharmacy meeting purity and good manufacturing practice standards and be dosed to the physiological premenopausal range. Trials underpinning the recommendation were largely conducted in women also taking systemic estrogen, and excluded populations at high cardiometabolic risk, so safety cannot be extrapolated freely. Free testosterone by equilibrium dialysis or calculated from total testosterone and SHBG is more informative than direct free testosterone immunoassay, which performs poorly at female concentrations.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism. PMID 31498871
- Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration
- Hormone Therapy. The Menopause Society
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.